Measuring alpha-synuclein changes in Parkinson's disease progression
Part of Brain & nervous system clinical trials.
This study examines changes in alpha-synuclein, a protein linked to Parkinson's, to better understand how the disease progresses. It may help researchers learn more about Parkinson's and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Parkinson's disease based on standard criteria and are in stages I to IV when on medication.
- You are willing to take part and can give permission (or have a legal representative who can).
- If you do not have Parkinson's, you must have a normal neurological exam and medical records available for review.
- You do not have severe memory or thinking problems, uncontrolled epilepsy, stroke, or other serious brain or muscle conditions.
- You do not have a fever, acute infection like flu or COVID-19, or a chronic infection such as hepatitis C, HIV, or tuberculosis.
- You do not have another life-threatening illness or condition that could affect the study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Parkinson's disease over time to learn more about the condition and how it progresses. By joining, you can help researchers better understand Parkinson's and improve future care.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This study looks for changes in a protein called alpha-synuclein in people who may be in the early “prodromal” stage before Parkinson’s symptoms fully appear. It may help researchers find early markers and understand who is more likely to develop Parkinson’s disease.
This study looks at how a protein called alpha-synuclein spreads in Parkinson's disease by checking blood and brain scans. It aims to understand why some people develop Parkinson's and to find clues that could lead to better treatments.
This study is testing whether a simple blood test can help doctors better understand Parkinson's disease by looking at how a protein called alpha-synuclein behaves. It aims to find a new way to diagnose and track the disease.
This study looks for new markers in the blood or other samples to help diagnose Parkinson's disease earlier. It compares people with Parkinson's, related conditions (like multiple system atrophy or progressive supranuclear palsy), and healthy volunteers to find differences.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.